Key facts
- It has raised $5.2M; the latest was Seed Round ($5.2M) in Dec 2024.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Dragon Pain Relief
- ·The full record, as it builds
Funding rounds
No funding rounds for Dragon Pain Relief are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dragon Pain Relief
Manufacturer of a topical pain relief drug intended to provide temporary relief from minor pain and inflammation. The company's product offers relief from muscle soreness, joint pain, and arthritis, and is formulated with a blend of natural ingredients, including menthol, camphor, ancient herbs, terpenes, and nano-emulsified cannabinoids, enabling customers seeking natural pain management to target deep-penetrating relief for muscle or inflammatory discomfort without relying on traditional medications.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Bellingham, WA, United States
- Founded
- 2022
- Employees
- 12
- Website
- dragonpainrelief.com/
- Ownership
- Privately Held (backing)
Dragon Pain Relief doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dragon Pain Relief shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dragon Pain Relief in its N-PORT filings yet. We sweep new filings monthly.